Opportunistic autoimmune disorders

From immunotherapy to immune dysregulation

Yi Chi M Kong, Wei Zen Wei, Yaron Tomer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.

Original languageEnglish (US)
Pages (from-to)222-236
Number of pages15
JournalAnnals of the New York Academy of Sciences
Volume1183
DOIs
StatePublished - Jan 10 2010
Externally publishedYes

Fingerprint

Immunotherapy
Autoimmune Diseases
Hepatitis C
Stem cells
Interferons
Modulation
Transplants
Chemotherapy
T-cells
Hematopoietic Stem Cell Transplantation
Thyroid Diseases
Immunologic Factors
Regulatory T-Lymphocytes
Major Histocompatibility Complex
Autoimmunity
Causality
Tumors
Immunity
Neoplasms
Thyroid Gland

Keywords

  • Autoimmunity
  • Immune dysregulation
  • Immunotherapeutic sequelae
  • Immunotherapy
  • Opportunistic autoimmunity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Opportunistic autoimmune disorders : From immunotherapy to immune dysregulation. / Kong, Yi Chi M; Wei, Wei Zen; Tomer, Yaron.

In: Annals of the New York Academy of Sciences, Vol. 1183, 10.01.2010, p. 222-236.

Research output: Contribution to journalArticle

@article{56bd661b44bf4f3eb9326d970f36f806,
title = "Opportunistic autoimmune disorders: From immunotherapy to immune dysregulation",
abstract = "Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.",
keywords = "Autoimmunity, Immune dysregulation, Immunotherapeutic sequelae, Immunotherapy, Opportunistic autoimmunity",
author = "Kong, {Yi Chi M} and Wei, {Wei Zen} and Yaron Tomer",
year = "2010",
month = "1",
day = "10",
doi = "10.1111/j.1749-6632.2009.05138.x",
language = "English (US)",
volume = "1183",
pages = "222--236",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Opportunistic autoimmune disorders

T2 - From immunotherapy to immune dysregulation

AU - Kong, Yi Chi M

AU - Wei, Wei Zen

AU - Tomer, Yaron

PY - 2010/1/10

Y1 - 2010/1/10

N2 - Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.

AB - Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.

KW - Autoimmunity

KW - Immune dysregulation

KW - Immunotherapeutic sequelae

KW - Immunotherapy

KW - Opportunistic autoimmunity

UR - http://www.scopus.com/inward/record.url?scp=75749141271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749141271&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.05138.x

DO - 10.1111/j.1749-6632.2009.05138.x

M3 - Article

VL - 1183

SP - 222

EP - 236

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -